Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease

Journal of Neuroscience

Volumn 26, Issue 35, 2006, Pages 9047-9056

  Green, Kim N ^a   Billings, Lauren M ^a   Roozendaal, Benno ^a   McGaugh, James L ^a   LaFerla, Frank M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

A peptide; Alzheimer's disease; Corticosterone; Glucocorticoids; Stress; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLUCOCORTICOID; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; STRESS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BRAIN; CELL LINE; CORTICOSTERONE; DENDRITES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; GLUCOCORTICOIDS; MALE; MICE; MICE, TRANSGENIC; NEURONS; SOLUBILITY; STRESS; TAU PROTEINS; TIME FACTORS; TRANSGENES;

EID: 33748253471     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2797-06.2006     Document Type: Article

References (41)

1. Abraham I, Harkany T, Horvath KM, Veenema AH, Penke B, Nyakas C, Luiten PG (2000) Chronic corticosterone administration dosedependently modulates Abeta(1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol 12:486-494.
2. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54:588-593.
3. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45:675-688.
4. Braak H, Braak E (1997) Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 18:S85-S88.
5. Budas G, Coughlan CM, Seckl JR, Breen KC (1999) The effect of corticosteroids on amyloid beta precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci Lett 276:61-64.
6. Dallman MF (2005) Fast glucocorticoid actions on brain: back to the future. Front Neuroendocrinol 26:103-108.
7. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, Johns CA, Horvath TB (1986) Cortisol and Alzheimer's disease. I. Basal studies. Am J Psychiatry 143:300-305.
8. de Quervain DJ, Poirier R, Wollmer MA, Grimaldi LM, Tsolaki M, Streffer JR, Hock C, Nitsch RM, Mohajeri MH, Papassotiropoulos A (2004) Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet 13:47-52.
9. Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM (1993) Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. J Neurochem 61:57-67.
10. Ge YW, Maloney B, Sambamurti K, Lahiri DK (2004) Functional characterization of the 5′ flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J 18:1037-1039.
11. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97:395-406.
12. Goodman Y, Bruce AJ, Cheng B, Mattson MP (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 66:1836-1844.
13. Greenwald BS, Mathe AA, Mohs RC, Levy MI, Johns CA, Davis KL (1986) Cortisol and Alzheimer's disease. II. Dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry 143:442-446.
14. Harris-White ME, Chu T, Miller SA, Simmons M, Teter B, Nash D, Cole GM, Frautschy SA (2001) Estrogen (E2) and glucocorticoid (Gc) effects on microglia and A beta clearance in vitro and in vivo. Neurochem Int 39:435-448.
15. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV (2005) Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 25:5217-5224.
16. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843-8853.
17. Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S (2005) Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J Neuropathol Exp Neurol 64:139-146.
18. Lahiri DK (2004) Functional characterization of amyloid β precursor protein regulatory elements: rationale for the identification of genetic polymorphism. Ann NY Acad Sci 1030:282-288.
19. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120:701-713.
20. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862.
21. Masugi F, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, Morimoto S, Kumahara Y, Saeki S, Nishide M (1989) High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type. Methods Find Exp Clin Pharmacol 11:707-710.
22. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
23. Molchan SE, Hill JL, Mellow AM, Lawlor BA, Martinez R, Sunderland T (1990) The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. Int Psychogeriatr 2:99-122.
24. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
25. Nasman B, Olsson T, Viitanen M, Carlstrom K (1995) A subtle disturbance in the feedback regulation of the hypothalamic-pituitary-adrenal axis in the early phase of Alzheimer's disease. Psychoneuroendocrinology 20:211-220.
26. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421.
27. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332.
28. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA (2001) Increased CSF cortisol in AD is a function of APOE genotype. Neurology 56:1094-1098.
29. Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505-2511.
30. Roozendaal B (2000) 1999 Curt P. Richter Award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 25:213-238.
31. Roozendaal B, Phillips RG, Power AE, Brooke SM, Sapolsky RM, McGaugh JL (2001) Memory retrieval impairment induced by hippocampal CA3 lesions is blocked by adrenocortical suppression. Nat Neurosci 4:1169-1171.
32. Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK (2004) Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 18:1034-1036.
33. Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R (1994) Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci 14:5373-5380.
34. Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA (1998) Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 155:286-289.
35. Terzic N, Vujcic M, Ristic-Fira A, Krstic-Demonacos M, Milanovic D, Kanazir DT, Ruzdijic S (2003) Effects of age and dexamethasone treatment on glucocorticoid response element and activating protein-1 binding activity in rat brain. J Gerontol A Biol Sci Med Sci 58:297-303.
36. Travis J (1993) New piece in Alzheimer's puzzle. Science 261:828-829.
37. Umegaki H, Ikari H, Nakahata H, Endo H, Suzuki Y, Ogawa O, Nakamura A, Yamamoto T, Iguchi A (2000) Plasma cortisol levels in elderly female subjects with Alzheimer's disease: a cross-sectional and longitudinal study. Brain Res 881:241-243.
38. Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2001) Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol 166:7496-7503.
39. Wilson RS, Barnes LL, Bennett DA, Li Y, Bienias JL, Mendes de Leon CF, Evans DA (2005) Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology 64:380-382.
40. Wright AP, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, Carlstedt-Duke J, Gustafsson JA (1993) Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 47:11-19.
41. Zhao M, Su J, Head E, Cotman CW (2003) Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis 14:391-403.